Cadrenal Therapeutics will be engaging with the FDA in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients. Left Ventricular Assist Devices – LVADs – are mechanical pumps to support heart function in patients with advanced heart failure.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
- Cadrenal Therapeutics Inc trading resumes
- Cadrenal Therapeutics Inc trading halted, volatility trading pause
- Cadrenal Therapeutics Inc trading halted, news pending
- Cadrenal Therapeutics Partners with Abbott on Cardiac Trial
- Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin